Starting and Monitoring Medications in Fragile X Syndrome — Presentation

Presented by Karen Regan, RN, and Nicole Tartaglia, MD

The decision to start or change medications for the treatment of behavioral or emotional symptoms in children with FXS can be challenging for parents and caregivers. This session, presented by two developmental pediatricians and a Fragile X Nurse, is designed for those considering starting medications for their child, and/or those who would like new strategies and approaches to considering medication changes. We will discuss criteria to consider when making decisions about medications and approaches to identify target symptoms in your child. We will present tools and strategies to track medication effectiveness and side effects, and strategies on how to work with your medical offices and providers to optimize follow-up. Finally, we will briefly review medications used for different symptoms of FXS, however details of medications are covered in other sessions.

Runtime: 1:16:20

About the Presenters

Karen Regan, RN

Children’s Hospital Colorado
Professional Research Assistant

Karen has worked with Dr. Tartaglia for 12 years as a nurse and research assistant with Fragile X families. She is the coordinator for FORWARD and FORWARD-MARCH at the Children’s Hospital Colorado.

Nicole Tartaglia, MD

University of Colorado School of Medicine
Professor of Pediatrics

Dr. Nicole Tartaglia completed her medical education at the University of Colorado School of Medicine, her residency in Pediatrics at Children’s Hospital Los Angeles, and her fellowship in Developmental Pediatrics at the UC-Davis MIND Institute. She is a Professor of Pediatrics at the University of Colorado School of Medicine. She has been director of the Denver Fragile X Clinic at Children’s Hospital Colorado since 2007, and proudly leads a team of dedicated clinical and research colleagues and mentees in Colorado. Dr. Tartaglia’s career is focused on clinical care and research in individuals with genetic causes of developmental disabilities, enjoys working closely with Fragile X families and the Fragile X research community nationally to help advance care and support for individuals with FXS and their families.